InteKrin Therapeutics, Inc.

InteKrin Therapeutics, Inc. (InteKrin) is a development stage biopharmaceutical company engaged in development and commercialization of innovative therapeutics for neuroendocrine, metabolic, and immune disorders. The company is actively pursuing development of treatments for insulin resistance, and obesity. The company develops INT131 as its lead product candidate for the treatment of Type 2 diabetes mellitus (T2DM) in phase II of clinical trials. INT131 is being developed as a non-TZD, selective peroxisome proliferator-activated receptor gamma modulator. The company is headquartered as Los Altos, California, the US.

Street: 
4300 El Camino Real
City: 
Los Altos
Postcode: 
94022
Federal State : 
United States
WebSite: 
www.intekrin.com
Fax: 
1-866-2862242

Company Index Score

Current Index Score Historical Index Score
  • InteKrin Therapeutics, Inc. currently scores 50 % in the index.
  • InteKrin Therapeutics, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • InteKrin Therapeutics, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets